SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021)

Autor: J. Remon, R. Bernabé, P. Diz, E. Felip, J. L. González-Larriba, M. Lázaro, X. Mielgo-Rubio, A. Sánchez, I. Sullivan, B. Massutti
Přispěvatelé: Institut Català de la Salut, [Remon J] Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Nou Delfos, HM Hospitales, Barcelona, Spain. [Bernabé R] Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain. [Diz P] Department of Medical Oncology, Hospital Universitario de León, León, Spain. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [González-Larriba JL] Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid, Spain. [Lázaro M] Department of Medical Oncology, Hospital Alvaro Cunqueiro, Vigo, Spain, Vall d'Hebron Barcelona Hospital Campus
Rok vydání: 2022
Předmět:
Cancer Research
Thymoma
administración de los servicios de salud::gestión de la atención al paciente::tratamiento de las enfermedades [ATENCIÓN DE SALUD]
Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]
Clinical Guides in Oncology
Other subheadings::Other subheadings::/drug therapy [Other subheadings]
neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del timo [ENFERMEDADES]
Decisió
Presa de
polycyclic compounds
Humans
Chemotherapy
Lenvatinib
Neoplasms
Glandular and Epithelial
Prospective Studies
Health Services Administration::Patient Care Management::Disease Management [HEALTH CARE]
neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales [ENFERMEDADES]
Multidisciplinary
Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Thymus Neoplasms [DISEASES]
General Medicine
Thymus Neoplasms
Neoplasms::Neoplasms by Histologic Type::Neoplasms
Glandular and Epithelial [DISEASES]
biochemical phenomena
metabolism
and nutrition
Thymic epithelial tumours
Nivolumab
Oncology
Epiteli - Càncer - Tractament
Zdroj: Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Scientia
CLINICAL & TRANSLATIONAL ONCOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
ISSN: 1699-3055
1699-048X
Popis: Chemotherapy; Lenvatinib; Thymic epithelial tumours Quimioterapia; lenvatinib; Tumores epiteliales tímicos Quimioteràpia; Lenvatinib; Tumors epitelials tímics Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due to the rarity of this disease, treatment decisions should be discussed in specific multidisciplinary tumour boards, and there are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.
Databáze: OpenAIRE
Externí odkaz: